SEC Form 4 · accession 0001838042-26-000003
Zentalis Pharmaceuticals, Inc. · ZNTL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jan Skvarka
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001725160
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 16, 2026 | A | 57,100 | $0.00 | A | 264,254 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Remarks
Exhibit 24 - Power of Attorney